Recente aanbestedingen waarbij de leverancier Convert Pharmaceuticals SA wordt genoemd
2020-06-22Hypoximmuno Project — CP-506 (Universiteit Maastricht)
To translate our promising preclinical findings on the hypoxia activated prodrug CP-506 into a new clinically available anticancer therapeutic, a phase I clinical trial needs to be initiated in patients with solid tumours with HR/FAN mutation. Through this tender, we are looking for an external partner that can provide CP-506 (as drug substance and drug product), manage the whole process and co-invest, in kind or in cash, in the project.
Bekijk de aanbesteding » Genoemde leveranciers:Convert Pharmaceuticals SA